The mission of the NRG Oncology Statistics and Data Management Center (SDMC) is to provide all necessary expertise and personnel for the design, conduct and analysis of clinical trials and associated research for NRG Oncology, a member group of the NCI National Clinical Trials Network (NCTN) program. The Administrative Core provides the components of the SDMC critical to a) leadership within the SDMC overall and between Core components, b) coordination with NRG Oncology Operations to effectively provide to the group necessary support for the research agenda and for investigators, including vital functions such as data and trial quality assurance and c) coordination with other Network groups and with the NCI to collectively meet the goals of the NCTN. The 2019-2024 cycle represents the second period of the NCTN program, which succeeded the NCI Cancer Cooperative Group program, of which NRG Oncology was formed by the unification of three existing Cooperative Groups. The re-organization to provide a structure that capitalizes on a wealth of skills and experience while avoiding inefficiencies was a challenge successfully met in the first cycle. The current leadership structure provides seamless work among sites under common procedures, with divisions organized by function rather than geography, while continuing to take advantage of longstanding expertise that may reside in a specific office (and thus are not redundant). Success during the first cycle is evidence by over 45 new trials either initiated or currently approved and in development, while accrual and/or follow-up to primary and secondary endpoint reporting on over 80 additional trials that were active at the inception of NRG Oncology. The NRG Oncology trials accruing during 2014-2017 represent 34% of all accruing NCTN trials. Publications from the group in the first cycle number well over 300, including 39 methodology articles by SDMC statisticians. The administrative structure of the SDMC has allowed it to serve as a highly functioning productive resource for NRG Oncology and the NCTN. In the second cycle of the NCTN, the Administrative Core will continue to enhance the integration of the group towards a seamless unit that serves all the operational needs of the SDMC as it carries out its mission. Specifically, the Administrative Core will provide the governance, strategic planning, scientific direction, logistical oversight, administrative resources and decision-making for the NRG Oncology Statistics and Data Management Center. The Core will lead critical liaisons with the NRG Operations Center, NCTN member groups, the NCI, pharmaceutical companies, and the FDA to ensure that research goals are met. The Core will provide quality assurance oversight to the other SDMC sections and to the NRG investigative sites, ensuring the integrity of the database and trial findings. Finally, the core will provide administrative resources and training to SDMC staff through adherence to its library of Standard Operating Procedures (SOPs).!

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180822-07
Application #
9901458
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-03-01
Budget End
2021-02-28
Support Year
7
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Timmerman, Robert D; Hu, Chen; Michalski, Jeff M et al. (2018) Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage I Non-Small Cell Lung Cancer. JAMA Oncol 4:1287-1288
Horowitz, Neil S; Larry Maxwell, G; Miller, Austin et al. (2018) Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 148:49-55
Matulonis, Ursula A; Sill, Michael W; Makker, Vicky et al. (2018) A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol :
Michalski, Jeff M; Moughan, Jennifer; Purdy, James et al. (2018) Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol 4:e180039
Boardman, Cecelia H; Brady, William E; Dizon, Don S et al. (2018) A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic On Gynecol Oncol 151:202-207
Blumenthal, Deborah T; Won, Minhee; Mehta, Minesh P et al. (2018) Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. Neuro Oncol 20:966-974
Hu, Chen; Steingrimsson, Jon Arni (2018) Personalized Risk Prediction in Clinical Oncology Research: Applications and Practical Issues Using Survival Trees and Random Forests. J Biopharm Stat 28:333-349
Bishop, Erin A; Java, James J; Moore, Kathleen N et al. (2018) Surgical outcomes among elderly women with endometrial cancerĀ treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol 218:109.e1-109.e11
Felix, Ashley S; Cohn, David E; Brasky, Theodore M et al. (2018) Receipt of adjuvant endometrial cancer treatment according to race: anĀ NRG Oncology/Gynecologic Oncology Group 210 Study. Am J Obstet Gynecol 219:459.e1-459.e11
Burger, Robert A; Deng, Wei; Makker, Vicky et al. (2018) Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 150:466-470

Showing the most recent 10 out of 331 publications